Patents by Inventor Xiaoxing Du

Xiaoxing Du has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 10208060
    Abstract: The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: February 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Alejandro Crespo, John Debenham, Xiaoxing Du, Ping Liu, Rongqiang Liu, Christina B. Madsen-Duggan, Weiguo Quan, Christopher Sinz, Liping Wang
  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 10000501
    Abstract: The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: June 19, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Vincent Colandrea, Alejandro Crespo, John Debenham, Xiaoxing Du, Deodialsingh Guiadeen, Ping Liu, Rongqiang Liu, Christina B. Madsen-Duggan, Joshua G. McCoy, Weiguo Quan, Christopher Sinz, Liping Wang
  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 9969752
    Abstract: The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Alejandro Crespo, Xiaoxing Du, Byron Gabriel Dubois, Deodialsingh Guiadeen, Shankaran Kothandaraman, Ping Liu, Rongqiang Liu, Weiguo Quan, Christopher Sinz, Liping Wang
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170313718
    Abstract: The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: November 2, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, ALEJANDRO CRESPO, JOHN DEBENHAM, XIAOXING DU, PING LIU, RONGQIANG LIU, CHRISTINA B. MADSEN-DUGGAN, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170247336
    Abstract: The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: October 8, 2015
    Publication date: August 31, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: FEZ UJJAINWALLA, JOHN QIANG TAN, QUN DANG, CHRISTOPHER J. SINZ, ALEJANDRO CRESPO, MING WANG, YILI CHEN, JIAQIANG CAI, FAN WU, XIAOXING DU
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170240555
    Abstract: The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 24, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, VINCENT COLANDREA, ALEJANDRO CRESPO, JOHN DEBENHAM, XIAOXING DU, DEODIALSINGH GUIADEEN, PING LIU, RONGQIANG LIU, CHRISTINA B. MADSEN-DUGGAN, JOSHUA G. MCCOY, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • SUBSTITUTED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170240511
    Abstract: The present invention concerns compounds of formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: October 8, 2015
    Publication date: August 24, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: FEZ UJJAINWALLA, JOHN QIANG TAN, QUN DANG, CHRISTOPHER J. SINZ, MING WANG, JIAQIANG CAI, XIAOXING DU, YILI CHEN
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170233412
    Abstract: The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 17, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, ALEJANDRO CRESPO, XIAOXING DU, BYRON GABRIEL DUBOIS, DEODIALSINGH GUIADEEN, SHANKARAN KOTHANDARAMAN, PING LIU, RONGQIANG LIU, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170226120
    Abstract: The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 10, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, ALEJANDRO CRESPO, XIAOXING DU, BYRON GABRIEL DUBOIS, PING LIU, RONGQIANG LIU, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors
    Patent number: 9725445
    Abstract: Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: August 8, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew Lloyd Childers, Christopher Dinsmore, Peter Fuller, David Guerin, Jason David Katz, Qinglin Pu, Mark E. Scott, Christopher F. Thompson, Hongjun Zhang, Danielle Falcone, Luis Torres, Jason Brubaker, Hongbo Zeng, Jiaqiang Cai, Xiaoxing Du, Chonggang Wang, Yunfeng Bai, Norman Kong, Yumei Liu, Zhixiang Zheng
  • CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
    Publication number: 20160280704
    Abstract: Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Application
    Filed: March 19, 2014
    Publication date: September 29, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Matthew Lloyd Childers, Christopher Dinsmore, Peter Fuller, David Guerin, Jason David Katz, Qinglin Pu, Mark E. Scott, Christopher F. Thompson, Hongjun Zhang, Danielle Falcone, Luis Torres, Jason Brubaker, Hongbo Zeng, Jiaqiang Cai, Xiaoxing Du, Chonggang Wang, Yunfeng Bai, Norman Kong, Yumei Liu, Zhixiang Zheng